John F. Paolini - 01 Sep 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Sep 2023
Net transactions value
-$28,308
Form type
4
Filing time
06 Sep 2023, 19:03:49 UTC
Previous filing
27 Jul 2023
Next filing
11 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +2,498 +6% 44,408 01 Sep 2023 Direct F1
transaction KNSA Class A Common Share Tax liability $13,036 -734 -1.7% $17.76 43,674 01 Sep 2023 Direct
transaction KNSA Class A Common Share Options Exercise +1,725 +3.9% 45,399 02 Sep 2023 Direct F1
transaction KNSA Class A Common Share Tax liability $9,004 -507 -1.1% $17.76 44,892 02 Sep 2023 Direct
transaction KNSA Class A Common Share Options Exercise $744 +400 +0.89% $1.86* 45,292 05 Sep 2023 Direct F2
transaction KNSA Class A Common Share Sale $7,012 -400 -0.88% $17.53 44,892 05 Sep 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -2,498 -25% $0.000000 7,492 01 Sep 2023 Class A Common Share 2,498 Direct F1, F4
transaction KNSA Restricted Share Unit Award $0 +6,496 $0.000000 6,496 01 Sep 2023 Class A Common Share 6,496 Direct F1, F5, F6
transaction KNSA Share Option Award $0 +38,974 $0.000000 38,974 01 Sep 2023 Class A Common Share 38,974 $17.76 Direct F6
transaction KNSA Restricted Share Unit Options Exercise $0 -1,725 -33% $0.000000 3,450 02 Sep 2023 Class A Common Share 1,725 Direct F1, F7
transaction KNSA Share Option Options Exercise $0 -400 -0.29% $0.000000 139,817 05 Sep 2023 Class A Common Share 400 $1.86 Direct F2, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $17.56. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.
F5 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.
F6 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
F7 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021.
F8 The option is fully vested and exercisable.